Article

Bisindolylmaleimides new inhibitors of CaM protein

Alejandro Sosa-Peinado1, Karina Fructuoso-García1, Luz Vasquez-Bochm2, and González-Andrade M1,\*

|  |
| --- |
| **Citation:** Lastname, F.; Lastname, F.; Lastname, F. Title. *Molecules* **2022**, *27*, x. https://doi.org/10.3390/xxxxx  Academic Editor: Firstname Lastname  Received: date  Accepted: date  Published: date  **Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.    **Copyright:** © 2022 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |

1 Laboratorio de Biosensores y Modelaje molecular, Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, México; [martin@bq.unam.mx](mailto:martin@bq.unam.mx) (M.G.-A.); [kaary.biology@gmail.com](mailto:kaary.biology@gmail.com) (K.F.-G.); [asosa@bq.unam.mx](mailto:asosa@bq.unam.mx) (A.S.-P.)

2 Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México, C.P 04510, México; [luz@bq.unam.mx](mailto:luz@bq.unam.mx) (L.V.-B)

**\*** Correspondence: Dr. Martin González-Andrade, Laboratorio de Biosensores y Modelaje molecular, Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, C.P 04510, México. E-mail address: [martin@bq.unam.mx](mailto:martin@bq.unam.mx)

**Abstract:** In the present study, we reported the interactions at the molecular level of a series of compounds called Bisindolylmaleimide, as potential inhibitors of the calmodulin protein. Bisindolylmaleimide compounds are drug prototypes derived from *Staurosporine*, an alkaloid with activity for cancer treatment. Bisindolylmaleimide compounds II, IV, VII, X, and XI, are proposed and reported as new inhibitors of calmodulin protein for the first time. For the above, a biotechnological device (fluorescent biosensor *h*CaM M124C-*mBBr*) to directly determine binding parameters experimentally (*K*d and stoichiometry) of these compounds and molecular modeling tools (Docking, Molecular Dynamics, and chemoinformatic analysis) to carry out the theoretical studies and complement the experimental data. The results indicate that this compound binds to the calmodulin with a *K*d between 193-248 nM, an order of magnitude lower than most classic inhibitors. On the other hand, the theoretical studies support the experimental results, obtaining an acceptable correlation between the GExperimental and GTheoretical (r2=0.703) and providing us with complementary molecular details of the interaction between the calmodulin protein and the Bisindolylmaleimide series. Chemoinformatic analyzes bring certainty to Bisindolylmaleimide compounds to address clinical steps in drug development. So, these results make this series of compounds attractive to be considered possible prototypes of new calmodulin protein inhibitors.

**Keywords:** Biosensors; Calmodulin; Bisindolylmaleimides; Anti-CaM drugs; Docking; Molecular dynamic; chemoinformatic.

1. Introduction

Bisindolylmaleimides (BIMs) are organics compounds derivates from indolocarbazoles, *staurosporine* formed by a maleimide group, and two indole groups bound to it [1]. A series of compounds have been synthesized from BIMs with different substituents in one of the indoles (Figure 1). This series includes BIM from I to XI, and biological activity has been reported for these compounds. BIM I has been reported as an inhibitor of protein kinase C (PKC) [2] and glycogen synthase kinase 3 (GSK3) [3], as well as a competitive antagonist at the 5-HT3 receptor [4]. BIM II is a general inhibitor of all PKC [5]. BIMs I, II, III, IV, and V interact and inhibit ABCG2 (a transporter with potential importance in cancer drug resistance) [6]. BIM IV, in addition to inhibiting the PKC also inhibits the cAMP-dependent protein kinase (PKA) [5]. BIM I, BIM II, BIM III, BIM VI, BIM VII, and BIM-VIII inhibit solute carrier organic cation transporter (OCT) 1, involved in the uptake of marketed drugs in the liver [7]. BIM IX is a potent inhibitor of GSK-3 [3]. BIM X is also considered an inhibitor of protein kinases (PKs) [8]. BIM XI inhibits PKC and prevents T-cell activation and proliferation [9, 10].



**BIM-II**

**BIM-III**

**BIM-VII**




**BIM-XI**

**BIM-X**

**Figure 1**. Chemical Structures of BIMs

A molecular target drug that interacts with many molecules and hence regulates many metabolic pathways is the protein calmodulin (CaM). In recent years, the CaM has been the subject of various computer, thermodynamic, structural, evolutionary, and pharmacological studies [5-11]. This protein is one of the most abundant, ubiquitous, and conserved, more than 60% of which are conserved among eukaryotes and 100% among vertebrates [12]. The sequence of CaM comprises 148 amino acids (16.7 KDa) formed by two domains containing each domain two Ca2+-binding loops known as EF-hand. CaM has no enzymatic activity but plays an essential role in calcium signaling pathways. CaM interacts with a large number of proteins to activate or regulate the concentration of calcium intracellular [11, 12]. CaM adopts three important conformations: Apo-CaM in the absence of calcium, Holo-CaM after binding Ca+2 ions where it exposes hydrophobic patches which are essential for the interaction and modulation of other proteins, and finally, the closed conformation where the protein it interacts with its inhibitors (drugs or peptides) and in this conformation it is unable to perform its function (Figure 2) [13, 14]. This protein is a molecular target of compounds with pharmacological activity, such as anti-cancers, antipsychotics, antidepressants, muscle relaxants, and local anesthetics. Moreover, it is involved in physiological processes such as muscle contraction, fertilization, cell proliferation, vesicular fusion, apoptosis, and others [15-19].

Studies of the physicochemical and structural properties of various CaM inhibitors have shown ionic and hydrophobic interactions between the ligands and CaM. The structural relationships between these ionic and hydrophobic regions and other factors such as the structure of the ligands (mainly resonant rings, large and hydrophobic structures, and halogens present), ionic forces, and electrostatic interactions, so far identified, are important and necessary factors for binding. Of molecules to CaM, not only is an isolated characteristic necessary for the correct interaction, some characteristics may even dominate more than others, but that depends on the nature of the compound itself [20]. Many known compounds that inhibit CaM have structural similarities, suggesting that the geometric structure of a bioactive molecule is essential in determining its interaction with CaM. In many cases, slight modifications in chemical structure can significantly alter a compound's ability to bind to CaM and inhibit its activity. A direct detection tool developed by our group is the calmodulin biosensor (*h*CaM-M124C-*mBBr*), which we have used to detect the binding of various ligands [21-28]. On the other hand, theoretical and computational studies, such as cheminformatics, docking, and molecular dynamics simulations (MD), are considered tools of great value to complement the experimental data. Therefore, this work uses experimental techniques and computational tools to propose new CaM inhibitors as possible prototypes of anti-CaM drugs.



**Figure 2**. Structure three-dimensional models of the CaM in its three main conformations. Apo-CaM was resolved by NMR (1CFD.pdb), Holo-CaM with its four occupied binding sites shown in green spheres (1CLL.pdb), and the Ca+2-CaM-TFP complex corresponding to the closed form of the protein (1LIN.pdb).

**2. Results and Discussion**

*2.1 Determination of the Kds of the BIM compounds using the fluorescent biosensor hCaM-M124C-mBBr*

Figure 3 shows the spectra and fluorescence titrations of the BIMs with the *h*CaM-M124C-*mBBr* biosensor. This device can measure the direct interaction of CaM ligands with great sensitivity and obtain binding parameters (*K*d and stoichiometry). All compounds exhibit a quenching of fluorescence intensity upon interaction with CaM. The estimated Kds are in the nM order, with the following affinity order: BIM-VII > BIM-XI > BIM-IV > BIM-X > BIM-II > CPZ (Table 1); which makes this series of compounds desirable to be considered as new anti-CaM drugs. Many of the inhibitors reported so far are in the micromolar range, such as KAR-2 (5 mM) [29], Imipramine (14 mM) [30], Serotonin (0.71 mM), Chlorpromazine (0.97 mM) [27], Trifluoperazine (1 mM), W7 (7 mM) [31] and Lubeluzole (2.9 mM) [32]; only some peptides in the nanomolar range [33]. On the other hand, the union stoichiometry of the compounds is from the ratio of 1:2 to 1:4, which is mainly attributed to the size of each particular compound.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 1**. Experimental and theoretical binding properties of Ca2+-CaM-BIMs complexes. | | | | | | |
|  | **Experimental studies** | | **Docking studies** | | | |
|  | ***K*d (nM)** | **stoichiometry** | ***K*i (nM)** | | | |
|  |  |  | **Site I** | **Site II** | **Site III** | **Site IV** |
| **Ca2+-CaM -BIM-II** | 257.8 ± 5.5 | 2.5 ± 0.2 | 109.79 | 161.58 | - | - |
| **Ca2+-CaM -BIM-IV** | 223.8 ± 3.7 | 3.7 ± 0.2 | 17.10 | 3390 | 7450 | - |
| **Ca2+-CaM -BIM-VII** | 186.2 ± 4.1 | 4.4 ± 0.1 | 2.14 | 26.95 | 52.43 | 263.87 |
| **Ca2+-CaM -BIM-X** | 205.2 ± 3.8 | 4.3 ± 0.1 | 20.36 | 59.39 | 71.65 | 217.1 |
| **Ca2+-CaM -BIM-XI** | 239.0 ± 5.0 | 3.4 ± 0.1 | 9.66 | 55.96 | 75.12 | 191.71 |
| **Ca2+-CaM -CPZ** | 492.2 ± 4.6 | 3.4 ± 0.1 | 715.65 | 1169 | 1640 | - |
| **Ca2+-CaM -TFP** | - | - | 384 | 707 | 959 | 976 |
|  | | | | | | |






****

**Figure 3.** Fluorescence spectra and titration curves of Ca+2-*h*CaM M124C-*mBBr* with BIM-II (A), BIM-IV (B), BIM-VII (C), BIM-X (D), BIM-XI (E), and CPZ (F). Buffer was 10 mM of potassium acetate pH 5.1 at 37 °C. The absolute changes of maximal fluorescence emission were corrected for light scattering effects and plotted against the ligands to total protein ratio (insets). The continuous line in the insets comes from data fitting to the binding model (equation 1 in the experimental section) to obtain the *K*d.

*2.2 Docking studies of the BIMs series with the CaM protein*

Based on the experimental results, we carried out docking studies of the BIMs compounds on the CaM. It has been reported that CaM can bind to more than one ligand depending on its size; for example, the co-crystallized CaM-TFP complex is available in a 1:2 (1A29.pdb) or 1:4 (1LIN. pdb). Figure 4 shows the four trifluoperazine (TFP) binding sites on CaM. We calculate the theoretical *K*i of each TFP in the four positions, and based on the affinity; we designate the sites; thus, site I is the one with the best affinity, and site IV has the lowest affinity for TFP. The results are presented in Table 1; depending on the stoichiometry of the BIMs and CPZ, the theoretical *K*i was calculated for sites I, II, III, or IV. The four sites behave according to the TFP calculation. Site I have the best affinity in all cases, and site IV has the lowest affinity. A graph was constructed to establish a relationship between the calculations obtained experimentally and theoretically (Figure 5), using the experimental *K*d and the theoretical *K*i of site I; showing a linear relationship between the data with an r2 of 0.85. This correlation is good since, based on it, we can carry out a structure-function analysis of the BIMs series and address the interactions of the Ca+2-CaM-BIM complexes in detail. Both the experimental and docking data indicate that the affinity of the BIMs compounds is in the nM range.


**

**Figure 4**. Structural model of the CaM-TFP 1:4 complex, from the 1LIN.pdb code. The sites were designated according to the degree of affinity based on Dockig's studies.



**Figure 5**. Relationship between the experimental *K*d and the theoretical *K*i of the BIM ligands


The details at the molecular level of the different Ca+2-CaM-BIMs complexes are shown in Figure 6 and Table 2; all the ligands bind in the same region, made up of primarily hydrophobic residues (Table 4). Theoretical *K*i, calculated by AutoDock4 presented in Table 3, where the BIM-VII compound showed the lowest affinity (2.14 nM), has the highest number of contacts with negatively charged residues (4 for this case); while for the rest of the ligands they have only 1. Additionally, this ligand forms two hydrogen bonds with residues Glu7 and Met124. BIM-VII is the ligand that presented the lowest *K*d in the experimental binding studies (186.2 nM), which is in harmony with these theoretical results. This same tendency can be observed with the positive control (CPZ), where the *K*d and *K*i are the highest at 492 and 715 nM, respectively.




**Figure 6.** The structural model of the docking results with the BIM compounds in site I of the CaM. The interactions with the residues at 4 Å are shown in the periphery. The image was made with PyMOL and Maestro.

|  |  |
| --- | --- |
| **Table 2**. Interactions of BIM compounds with CaM from the site I docking | |
|  | **Interaction residuals** |
| **Ca2+-CaM-BIM-II** | Leu39, Ala88, Val91, Phe141, Phe92, Ile100, Leu105, Val108, Met109, Leu112, Met124, Ile125, Glu127, Val136 |
| **Ca2+-CaM-BIM-IV** | Glu127, Ile125, Met124, Leu105, Val108, Met109, Leu112, Leu39, Phe141, Phe92, Ile100, Val136 |
| **Ca2+-CaM-BIM-VII** | Glu7, Glu11, Glu14, Phe92, Phe141, Phe144, Leu105, Ile100, Val136, Met124, Ile125, Met109, Glu127 |
| **Ca2+-CaM-BIM-X** | Met124, Glu127, Phe92, Ile100, Leu112, Met109, Val108, Leu39, Phe141, Met144, Met145 |
| **Ca2+-CaM-BIM-XI** | Val136, Phe92, Ile100, Ala128, Glu127, Ile125, Met124, Lys148, Ala147, Met145, Met144 |
| **Ca2+-CaM -CPZ** | Glu127, Ile125, Met124, Leu105, Val136, Ile100, Phe92, Phe141, Met144 |
|  | |

*2.3 Molecular dynamics simulation studies*

******The MD studies of the Ca2+-CaM-BIM complexes were carried out to obtain dynamic-structural and energetic information about this series of compounds. The MD was performed up to 200 ns, a reasonable time to evaluate the desired energetic and structural parameters. Figure 7 shows the structural models generated from the MD trajectories for Ca2+-CaM, Ca2+-CaM-BIM-VII, and Ca2+-CaM-CPZ complexes, where we can observe that the protein in the closed state without ligands after 50 ns tends to open. In comparison, the complexes remain closed until 200 ns. This behavior can be attributed to the ligands providing stability to the closed CaM conformation. At the same time, the free protein can transit between the closed and open states in a dynamic equilibrium.



**Figure 7**. Structural models of the molecular dynamics simulation of Ca2+-CaM and the Ca2+-CaM-BIS-VII and, Ca2+-CaM-CPZ complexes (200 ns).

**

**Figure 8**. The RMSD & Time plot for 200 ns MD simulation. Shows the differences between closed CaM and CaM-BIM-II, CaM-BIM-IV, CaM-BIM-VII, CaM-BIM-X, CaM-BIM-XI, and CaM-CPZ.

Figure 8 shows the Root Mean Square Deviation (RMSD) as a function of time, where we can observe the difference between CaM without ligand and CaM with BIMs. This difference in RMSD is mainly related to the structural stability of CaM, where all CaM-BIS complexes have a lower RMSD (between 2 and 4 Å), while ligand-free CaM has an RMSD of around 6 Å.

**Site IV**



**SiteI**

**Site II**

**Site III**

**C-Terminal**

**N-Terminal**

**Figure 9.** RMSF vs Time of CaM-BIS complexes and three-dimensional model of CaM highlighting calcium ion binding sites in red spheres

Another parameter we evaluate in the MD is the Root Mean Square Fluctuations (RMSF) by amino acids of the CaM, where we observe which areas of the protein with greater and lesser flexibility. Figure 9 shows us in a general way that the lobe corresponding to the C-terminal of the CaM is considerably more flexible, as well as the zones corresponding to the four calcium binding sites. In the lobe corresponding to the C-Terminal are the amino acids that interact with the BIMs in site I, according to docking studies, which makes sense due to the flexibility of this region. Comparing the RMSF of CaM in the absence or presence of the ligands, we can observe that the BIMs and CPZ compounds confer less flexibility to CaM in all its regions, which makes the complexes more stable in general.

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 3**. Theoretical energy parameters of the Ca2+-CaM-BIM complexes from the MD studies. | | | |
|  | **DG (Kcal/mol)** | **DH (Kcal/mol)** | **DS (Kcal/mol)** |
| **Ca2+-CaM-BIM-II** | -42.73±9.64 | -67.61±3.88 | -24.87±8.82 |
| **Ca2+-CaM-BIM-IV** | -30.25±3.91 | -47.61±3.29 | -17.36±2.10 |
| **Ca2+-CaM-BIM-VII** | -49.48±6.92 | -72.65±5.11 | -23.17±4.67 |
| **Ca2+-CaM-BIM-X** | -23.57±5.19 | -49.64±3.31 | -26.06±4.00 |
| **Ca2+-CaM-BIM-XI** | -45.47±9.67 | -71.21±5.23 | -25.74±8.13 |
| **Ca2+-CaM-CPZ** | -16.77±5.77 | -35.01±4.53 | -18.24±3.58 |

The theoretical energy parameters calculated from the MD trajectories are shown in Table 3. All the complexes have a negative G, the majority contribution given by the enthalpy component (H). The entropic component (S) is lower in all cases, which is associated with the stability of the CaM-Ligand complexes. The BIM-VII compound has the lowest G (-49.48 Kcal/mol), which agrees with the experimental and docking data where this compound has the best affinity (186.2 and 2.14 nM, respectively). At the other extreme, we have a positive control (CPZ), which has the lowest affinity (492.2 nM) and the highest G of all the ligands studied; this relationship indicates that the MD studies are an excellent option to complement our experimental results and to be able to predict good results in subsequent theoretical studies.

*2.4 Chemoinformatic analysis*

One of the main problems in developing possible bioactive molecules to be considered potential drugs is that the last stages of clinical trials are not satisfactory; one way to reduce this probability is through chemoinformatic studies. Table 4 shows the cheminformatic properties of the BIM compounds, this information based on computational theoretical information predicts some crucial parameters to evaluate the possibility that any of the compounds proposed in work could be considered a drug candidate. Within these parameters, we can highlight the drug score, which evaluates all the desirable characteristics of a molecule to be considered a drug; the range is from 0 to 1, being better the closer it is to 1; for our compounds, this parameter is found in the range of 0.64 to 0.92. Another parameter to highlight that directly affects a compound's affinity (power) for possible molecular targets is hydrogen bonds. The BIM series has a greater probability of accepting hydrogen bonds than donating, with BIM-VII being the compound that can accept up to 7, which also agrees with the best affinity and the lowest theoretical binding energy (Docking and MD). Finally, the calculated partition coefficient (cLogP) indicates the degree of hydrophobicity of a molecule; an essential parameter for the absorption of this in biological systems since most drugs have to cross cell membranes to reach molecular targets within cells. The BIMs have a cLogP between 1.55 and 3.02, acceptable ranges. In general, this chemoinformatic analysis predicts that the BIM series has a good chance that one of the compounds will be considered a potential anti-CaM drug candidate.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 4**. Chemoinformatic properties of the BIM and CPZ compounds. | | | | | | |
| **Compound** | **BIM-II** | **BIM-IV** | **BIM-VII** | **BIM-X** | **BIM-XI** | **CPZ** |
| **cLogP** | 2.43 | 1.58 | 1.55 | 2.4 | 3.02 | 4.61 |
| **Solubility (LogS)** | -3.38 | -3.55 | -2.55 | -3.23 | -2.78 | -4.8 |
| **Molecular weight** | 438.53 | 327.34 | 453.54 | 425.5 | 452.56 | 318.87 |
| **Druglikeness** | 7.73 | 4.21 | 6.81 | 6.65 | 8.05 | 8.38 |
| **H bond acceptor** | 6 | 5 | 7 | 6 | 6 | 2 |
| **H bond donor** | 2 | 3 | 3 | 2 | 1 | 0 |
| **Stereocenters** | 1 | 0 | 0 | 1 | 1 | 0 |
| **Rotatable bonds** | 5 | 2 | 6 | 3 | 4 | 4 |
| **Drug score** | 0.81 | 0.92 | 0.64 | 0.83 | 0.77 | 0.45 |
| The data was calculated using the OSIRIS server <http://www.cheminfo.org/Chemistry/Cheminformatics/Property_explorer/index.html> | | | | | | |

3. Materials and Methods

*3.1 Chemistry*

The biosensor (*h*CaM M124C-*mBBr*) was obtained using the methodology described above by González-Andrade, M., and *col*. [26]. The drugs and BIMs were acquired from Sigma (St. Louis, MO) and Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA). All other reagents were of analytical grade and purchased from Sigma (St. Louis, MO).

*3.2 Steady-state fluorescence*

All measurements were conducted with an ISS–PC1 spectrofluorometer (ISS, Champaign, IL) with a sample stirring at 37 ºC. The *h*CaM M124C-*mBBr* (1 M) was incubated in buffer (10 mM of potassium acetate [pH 5.1] and 10 M of CaCl2). Fluorescence emission spectra were acquired with excitation and emission slit widths of 4 and 8 nm, respectively. The excitation wavelength was 381 nm, and emission wavelengths of 415 to 550 nm were measured. The fractional degree of saturated *h*CaM M124C-*mBBr* with ligand (*y*) was calculated by changes in fluorescence on ligand binding according to *y* = (F-F0) / (F∞-F0), where F∞ represents the fluorescence intensity at saturation of the ligand, *y* is plotted as a function of the protein/ligand relation (*L*), and the apparent dissociation constants (*K*d) and stoichiometric (*S*) were obtained by fitting to the equation:

 (Equation 1)

where *y* represents the fractional degree of fluorescence intensity at 470 nm, *K*d is the apparent dissociation constant for the ligands, *L* is the protein/ligand relation, and *S* is stoichiometric. The data were analyzed using the OriginPro version 9.0 64-bit SR2 program (OriginLab, Northampton, MA).

*3.3 Preparation of initial coordinate files*

The coordinates corresponding to the structure of CaM were obtained from the Protein Data Bank (PDB, http://www.rcsb.org). The CaM-ligands complexes, the X-ray structure of CaM with calcium and TFP named 1LIN.pdb (1LIN, close form of the CaM) refined at 2.0 Å were chosen [34]. The ligands were obtained from the PDB co-crystillized structure, and when the crystals were not available, their structures were constructed using HyperChem 8 software. All structures of the ligands were minimized using Gaussian 09, revision A.02 (Gaussian Inc., Wallingford, CT) at DTF B3LYP/3-21G level of theory. The inhibitors' partial charges and force field parameters were generated automatically using the *antechamber* program in AmberTools22 [35].

*3.4 Docking studies*

Docking was conducted using PDB X-ray structure of the CaM with the ligand TFP (1A29.pdb). We performed a final all-atom refinement of CaM with the idealization application of the Rosetta3.1 release [36]. All compounds were built using the HyperChem 8.0 release program and optimized geometrically using the Gaussian 09 program, revision A.02 (Gaussian Inc., Wallingford, CT) at DTF B3LYP/3-21G level of theory. The protein and ligands were further prepared using the utilities implemented by AutoDockTools 1.5.4 (http://mgltools.scripps.edu/). The protein added polar hydrogen atoms, Kollman united-atom partial charges, and to the ligands computing Gasteiger-Marsilli formalism charges, rotatable groups were assigned automatically, as were the active torsions. Blind docking was carried out using AutoDock4 version 4.2 software (<http://autodock.scripps.edu/>) [37-39], using the default parameters the Lamarkian genetic algorithm with local search, number of individuals in a population (150), maximum number of energy evaluations (2.5 million), maximum number of generations (27 000), rate of gene mutation (0.02), rate of crossover (0.8) and 100 runs for docking. Electrostatic grid maps were generated for each atom type in the ligands using the auxiliary program AutoGrid4 part of the software AutoDock4. The initial grid box size was 60Å x 60Å x 60Å in the x, y, and z dimensions. In order to refine the docking analyses, they were performed in a smaller grid box, with 30Å x 30Å x 30Å dimensions, placed in the ligand. The docking analysis was made with AutoDockTools using cluster analysis and the program PyMOL [40].

*3.5 Molecular dynamics simulation studies*

The coordinates of the ligands resulting from the docking study were processed with *antechamber* (a set of auxiliary programs for molecular mechanic studies) to generate suitable topologies for the LEaP module from AmberTools22 [35, 41-43]. Each structure and complex were subjected to the following protocol: hydrogen and other missing atoms were added using the LEaP module with the parm99 parameter set (PARM99 + frcmod.ff99SB + frcmod.parmbsc0 + OL3 for RNA + ff19SB), Na+ counterions were added to neutralize the system, the complexes were then solvated in an octahedral box of explicit TIP3P model water molecules localizing the box limits at 12 Å from the protein surface. MD simulations were performed at 1 atm and 298 K, maintained with the Berendsen barostat and thermostat, using periodic boundary conditions and particle mesh Ewald sums (grid spacing of 1 Å) for treating long-range electrostatic interactions with a 10 Å cutoff for computing direct interactions. The SHAKE algorithm was used to satisfy bond constraints, allowing the employment of a 2 fs time step to integrate Newton's equations as recommended in the Amber package [42, 44]. Amber f99SB force field [43, 45, 46] parameters were used for all residues, and Gaff force field [47, 48] parameters were used for the ligands. All calculations were made using graphics processing units (GPU, Tesla V100) accelerated MD engine in AMBER (pmemd.cuda), a program package that runs entirely on CUDA-enabled GPUs [49]. The protocol consisted in performing an optimization of the initial structure, followed by 50 ps heating step at 298 K, 50 ps for equilibration at constant volume, and 500 ps for equilibration at constant pressure. Several independent 200 ns MD simulations were performed. Frames were saved at 100 ps intervals for subsequent analysis.

*3.6 Binding free energies calculated by molecular mechanics/poisson boltzmann surface area (MM/PBSA)*

This method combines molecular mechanics' energy with implicit solvation models to calculate binding free energies. In MM/PBSA [50, 51], binding free energy (ΔGbind) between a ligand (L) and a target (T) to form a complex is calculated as:

where Δ*E*MM, Δ*G*Sol, and −*T*Δ*S* are the changes of the gas phase molecular mechanics energy, the solvation free energy, and the conformational entropy upon binding, respectively. Δ*E*MM comprises Δ*E*Internal (bond, angle, and dihedral energies), Δ*E*Electrostatic (electrostatic energies), and Δ*E*Vdw (van der Waals energies). Δ*G*Solv is the sum of electrostatic solvation energy (polar contribution) -Δ*G*PB- and non-electrostatic solvation component (non-polar contribution) -Δ*G*SA-. The polar contribution is calculated using the Poisson-Boltzmann surface area model, while the non-polar energy is estimated from the solvent-accessible surface area (*SASA*). The conformational entropy change (-*TDS*) was computed by normal mode analysis from a set of conformational snapshots taken from the MD simulations [50, 52, 53].

*3.7 Trajectory Analysis*

The analyses were done using CPPTRAJ [49] part of AmberTools22 utilities and Origin 9.0. First, the RMSD and Root Mean Square Fluctuations (RMSF) calculations were made, considering the C, CA, and N; for the distances, only the CA was used. The charts were built with Origin 9.0, and the trends were adjusted with smooth function processing (method Lowess).

All calculations were made using a system HP Cluster Platform 3000SL, supercomputer "MIZTLI" with a processing capacity of 118 TFlop/s. It has 5,312 Intel E5-2670 processing cores, 16 NVIDIA m2090 cards, GPU Tesla V100, a total RAM of 15,000 Gbytes, and a mass storage system of 750 Terabytes (http://www.super.unam.mx/).

4. Conclusions

In this work, a series of compounds called BIM were evaluated as possible inhibitors of the CaM protein, which have not been described in the literature for this purpose. Binding assays using the *h*CaM-M124C-*mBBr* biosensor indicate that BIMs bind to CaM protein with a *K*d in the nM order, better than most classical inhibitors. Furthermore, the docking results confirm and complement the experimental results detailing the interactions at the molecular level of the BIMs with the CaM, while the MD describes the structural stability and theoretical thermodynamic parameters associated with the Ca2+-CaM-BIM complexes. Finally, the chemoinformatic analyzes predict some favorable data to consider this series of BIMs compounds as possible CaM inhibitors to be considered anti-CaM drugs.

**Author Contributions:** Conceptualization, M G-A., K. F-G., and A. S-P.; Data curation, M G-A., A. S-P., and K. F-G. Formal analysis M G-A., L. V-B, K. F-G, and A. S-P. Funding acquisition M G-A., and A. S-P. Investigation M G-A., K. F-G, A. S-P, and L. V-B. Methodology M G-A., K. F-G, L. V-B., and A. S-P. Software M G-A. and A. S-P. All authors discussed the contents of the manuscript.

**Funding:** This work was supported by grants from DGAPA-UNAM (PAPIIT-IN203222) and DGTIC-UNAM (LANCAD-UNAM-DGTIC-313), and the Research Division of the Medical School, UNAM.

**Acknowledgments:** The authors are very grateful to the Research Division of the Medical School, UNAM. We are indebted to Dirección General de Cómputo y de Tecnologías de Información y Comunicación, UNAM, for providing the resources to carry out computational calculations through Miztli System. The authors acknowledge the invaluable technical support of María Isabel Velázquez López, Eugenia Flores Robles, and Laura Iliana Alvarez Añorve.

**Conflicts of Interest:** The authors have declared no conflict of interest.

References

1. Faul, M. M.; Winneroski, L. L.; Krumrich, C. A., A New, Efficient Method for the Synthesis of Bisindolylmaleimides. *J Org Chem* **1998,** 63, (17), 6053-6058.

2. Toullec, D.; Pianetti, P.; Coste, H.; Bellevergue, P.; Grand-Perret, T.; Ajakane, M.; Baudet, V.; Boissin, P.; Boursier, E.; Loriolle, F.; et al., The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. *J Biol Chem* **1991,** 266, (24), 15771-81.

3. Hers, I.; Tavare, J. M.; Denton, R. M., The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. *FEBS Lett* **1999,** 460, (3), 433-6.

4. Coultrap, S. J.; Sun, H.; Tenner, T. E., Jr.; Machu, T. K., Competitive antagonism of the mouse 5-hydroxytryptamine3 receptor by bisindolylmaleimide I, a "selective" protein kinase C inhibitor. *J Pharmacol Exp Ther* **1999,** 290, (1), 76-82.

5. Davis, P. D.; Hill, C. H.; Lawton, G.; Nixon, J. S.; Wilkinson, S. E.; Hurst, S. A.; Keech, E.; Turner, S. E., Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. *J Med Chem* **1992,** 35, (1), 177-84.

6. Robey, R. W.; Shukla, S.; Steadman, K.; Obrzut, T.; Finley, E. M.; Ambudkar, S. V.; Bates, S. E., Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. *Mol Cancer Ther* **2007,** 6, (6), 1877-85.

7. Mayati, A.; Bruyere, A.; Moreau, A.; Jouan, E.; Denizot, C.; Parmentier, Y.; Fardel, O., Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220. *PLoS One* **2015,** 10, (12), e0144667.

8. Deane, F. M.; Lin, A. J. S.; Hains, P. G.; Pilgrim, S. L.; Robinson, P. J.; McCluskey, A., FD5180, a Novel Protein Kinase Affinity Probe, and the Effect of Bead Loading on Protein Kinase Identification. *ACS Omega* **2017,** 2, (7), 3828-3838.

9. Birchall, A. M.; Bishop, J.; Bradshaw, D.; Cline, A.; Coffey, J.; Elliott, L. H.; Gibson, V. M.; Greenham, A.; Hallam, T. J.; Harris, W.; et al., Ro 32-0432, a selective and orally active inhibitor of protein kinase C prevents T-cell activation. *J Pharmacol Exp Ther* **1994,** 268, (2), 922-9.

10. Bit, R. A.; Davis, P. D.; Elliott, L. H.; Harris, W.; Hill, C. H.; Keech, E.; Kumar, H.; Lawton, G.; Maw, A.; Nixon, J. S.; et al., Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. *J Med Chem* **1993,** 36, (1), 21-9.

11. Hoeflich, K. P.; Ikura, M., Calmodulin in action: diversity in target recognition and activation mechanisms. *Cell* **2002,** 108, (6), 739-42.

12. Tripathi, S.; Waxham, M. N.; Cheung, M. S.; Liu, Y., Lessons in Protein Design from Combined Evolution and Conformational Dynamics. *Scientific Reports* **2015,** 5, 14259.

13. Jurado, L. A.; Chockalingam, P. S.; Jarrett, H. W., Apocalmodulin. *Physiol Rev* **1999,** 79, (3), 661-82.

14. Komeiji, Y.; Ueno, Y.; Uebayasi, M., Molecular dynamics simulations revealed Ca(2+)-dependent conformational change of Calmodulin. *FEBS Lett* **2002,** 521, (1-3), 133-9.

15. Seales, E. C.; Micoli, K. J.; McDonald, J. M., Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival. *J Cell Biochem* **2006,** 97, (Copyright (C) 2011 U.S. National Library of Medicine.), 45-55.

16. Junker, J. P.; Ziegler, F.; Rief, M., Ligand-dependent equilibrium fluctuations of single calmodulin molecules. *Science* **2009,** 323, (5914), 633-7.

17. Weiss, B.; Prozialeck, W. C.; Wallace, T. L., Interaction of drugs with calmodulin. Biochemical, pharmacological and clinical implications. *Biochemical pharmacology* **1982,** 31, (13), 2217-26.

18. Mayur, Y. C.; Jagadeesh, S.; Thimmaiah, K. N., Targeting calmodulin in reversing multi drug resistance in cancer cells. *Mini Rev Med Chem* **2006,** 6, (12), 1383-9.

19. Mayur, Y. C.; Padma, T.; Parimala, B. H.; Chandramouli, K. H.; Jagadeesh, S.; Gowda, N. M.; Thimmaiah, K. N., Sensitization of multidrug resistant (MDR) cancer cells to vinblastine by novel acridones: correlation between anti-calmodulin activity and anti-MDR activity. *Med Chem* **2006,** 2, (1), 63-77.

20. Chin, D.; Means, A. R., Calmodulin: a prototypical calcium sensor. *Trends Cell Biol* **2000,** 10, (8), 322-8.

21. Gonzalez-Andrade, M.; Figueroa, M.; Rodriguez-Sotres, R.; Mata, R.; Sosa-Peinado, A., An alternative assay to discover potential calmodulin inhibitors using a human fluorophore-labeled CaM protein. *Anal Biochem* **2009,** 387, (1), 64-70.

22. Mata, R.; Figueroa, M.; Gonzalez-Andrade, M.; Rivera-Chavez, J. A.; Madariaga-Mazon, A.; Del Valle, P., Calmodulin inhibitors from natural sources: an update. *J Nat Prod* **2015,** 78, (3), 576-86.

23. González-Andrade, M.; Del Valle, P.; Macías-Rubalcava, M. L.; Sosa-Peinado, A.; Del Carmen González, M.; Mata, R., Calmodulin inhibitors from aspergillus stromatoides. *Chemistry and Biodiversity* **2013,** 10, (3), 328-337.

24. González-Andrade, M.; Benito-Peña, E.; Mata, R.; Moreno-Bondi, M. C., Biosensor for on-line fluorescent detection of trifluoroperazine based on genetically modified calmodulin. *Anal Bioanal Chem* **2012,** 402, (10), 3211-3218.

25. Figueroa, M.; González-Andrade, M.; Sosa-Peinado, A.; Madariaga-Mazón, A.; Del Río-Portilla, F.; Del Carmen González, M.; Mata, R., Fluorescence, circular dichroism, NMR, and docking studies of the interaction of the alkaloid malbrancheamide with calmodulin. *Journal of Enzyme Inhibition and Medicinal Chemistry* **2011,** 26, (3), 378-385.

26. González-Andrade, M.; Figueroa, M.; Rodríguez-Sotres, R.; Mata, R.; Sosa-Peinado, A., An alternative assay to discover potential calmodulin inhibitors using a human fluorophore-labeled CaM protein. *Analytical Biochemistry* **2009,** 387, (1), 64-70.

27. Vásquez-Bochm, L. X.; Velázquez-López, I.; Mata, R.; Sosa-Peinado, A.; Cano-Sánchez, P.; González-Andrade, M., Application of a Fluorescent Biosensor in Determining the Binding of 5-HT to Calmodulin. **2021,** 9, (9), 250.

28. Gonzalez-Andrade, M.; Rodriguez-Sotres, R.; Madariaga-Mazon, A.; Rivera-Chavez, J.; Mata, R.; Sosa-Peinado, A.; Pozo-Yauner, L. D.; Arias, O., II, Insights into molecular interactions between CaM and its inhibitors from molecular dynamics simulations and experimental data. *J Biomol Struct Dyn* **2015**, 1-14.

29. Orosz, F.; Vertessy, B. G.; Salerno, C.; Crifo, C.; Capuozzo, E.; Ovadi, J., The interaction of a new anti-tumour drug, KAR-2 with calmodulin. *Br J Pharmacol* **1997,** 121, (5), 955-62.

30. Sharma, B.; Deo, S. K.; Bachas, L. G.; Daunert, S., Competitive binding assay using fluorescence resonance energy transfer for the identification of calmodulin antagonists. *Bioconjug Chem* **2005,** 16, (5), 1257-63.

31. Juhasz, T.; Kardos, J.; Durvanger, Z.; Harmat, V.; Liliom, K., Comparison of ligand binding and conformational stability of human calmodulin with its homolog from the malaria parasite Plasmodium falciparum. *FASEB Bioadv* **2020,** 2, (8), 489-505.

32. Bruno, C.; Cavalluzzi, M. M.; Rusciano, M. R.; Lovece, A.; Carrieri, A.; Pracella, R.; Giannuzzi, G.; Polimeno, L.; Viale, M.; Illario, M.; Franchini, C.; Lentini, G., The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca(2+)/calmodulin-dependent kinase II. *Eur J Med Chem* **2016,** 116, 36-45.

33. Sosa-Peinado, A.; Leon-Cruz, E.; Velazquez-Lopez, I.; Matuz-Mares, D.; Cano-Sanchez, P.; Gonzalez-Andrade, M., Theoretical-experimental studies of calmodulin-peptide interactions at different calcium equivalents. *J Biomol Struct Dyn* **2020**, 1-12.

34. Vandonselaar, M.; Hickie, R. A.; Quail, J. W.; Delbaere, L. T., Trifluoperazine-induced conformational change in Ca(2+)-calmodulin. *Nat Struct Biol* **1994,** 1, (11), 795-801.

35. D.A. Case, H. M. A., K. Belfon, I.Y. Ben-Shalom, J.T. Berryman, S.R. Brozell, D.S. Cerutti, T.E. Cheatham, III, G.A. Cisneros, V.W.D. Cruzeiro, T.A. Darden, R.E. Duke, G. Giambasu, M.K. Gilson, H. Gohlke, A.W. Goetz, R. Harris, S. Izadi, S.A. Izmailov, K. Kasavajhala, M.C. Kaymak, E. King, A. Kovalenko, T. Kurtzman, T.S. Lee, S. LeGrand, P. Li, C. Lin, J. Liu, T. Luchko, R. Luo, M. Machado, V. Man, M. Manathunga, K.M. Merz, Y. Miao, O. Mikhailovskii, G. Monard, H. Nguyen, K.A. O’Hearn, A. Onufriev, F. Pan, S. Pantano, R. Qi, A. Rahnamoun, D.R. Roe, A. Roitberg, C. Sagui, S. Schott-Verdugo, A. Shajan, J. Shen, C.L. Simmerling, N.R. Skrynnikov, J. Smith, J. Swails, R.C. Walker, J. Wang, J. Wang, H. Wei, R.M. Wolf, X. Wu, Y. Xiong, Y. Xue, D.M. York, S. Zhao, and P.A. Kollman, Amber 2022. 2022.

36. Wedemeyer, W. J.; Baker, D., Efficient minimization of angle-dependent potentials for polypeptides in internal coordinates. *Proteins* **2003,** 53, (2), 262-72.

37. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J., Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *Journal of Computational Chemistry* **1998,** 19, (14), 1639-1662.

38. Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S., A semiempirical free energy force field with charge-based desolvation. *J Comput Chem* **2007,** 28, (6), 1145-52.

39. Moitessier, N.; Henry, C.; Maigret, B.; Chapleur, Y., Combining pharmacophore search, automated docking, and molecular dynamics simulations as a novel strategy for flexible docking. Proof of concept: docking of arginine-glycine-aspartic acid-like compounds into the alphavbeta3 binding site. *J Med Chem* **2004,** 47, (17), 4178-87.

40. DeLano, W. L., Use of PYMOL as a communications tool for molecular science. *Abstracts of Papers of the American Chemical Society* **2004,** 228, U313-U314.

41. D.A. Case, J. T. B., R.M. Betz, D.S. Cerutti, T.E. Cheatham, III, T.A. Darden, R.E. Duke, T.J. Giese, H. Gohlke, A.W. Goetz, N. Homeyer, S. Izadi, P. Janowski, J. Kaus, A. Kovalenko, T.S. Lee, S. LeGrand, P. Li, T. Luchko, R. Luo, B. Madej, K.M. Merz, G. Monard, P. Needham, H. Nguyen, H.T. Nguyen, I. Omelyan, A. Onufriev, D.R. Roe, A. Roitberg, R. Salomon-Ferrer, C.L. Simmerling, W. Smith, J. Swails, R.C. Walker, J. Wang, R.M. Wolf, X. Wu, D.M. York and P.A. Kollman *AMBER 2015*, 2015.

42. D.A. Case, T. A. D., T.E. Cheatham, III, C.L. Simmerling, J. Wang, R.E. Duke, R. Luo, R.C. Walker, W. Zhang, K.M. Merz, B. Roberts, S. Hayik, A. Roitberg, G. Seabra, J. Swails, A.W. Goetz, I. Kolossvai, K.F. Wong, F. Paesani, J. Vanicek, R.M. Wolf, J. Liu, X. Wu, S.R. Brozell, T. Steinbrecher, H. Gohlke, Q. Cai, X. Ye, J. Wang, M.-J. Hsieh, G. Cui, D.R. Roe, D.H. Mathews, M.G. Seetin, R. Salomon-Ferrer, C. Sagui, V. Babin, T. Luchko, S. Gusarov, A. Kovalenko, and P.A. Kollman, AMBER 12. University of California, San Francisco, 2012.

43. Case, D. A.; Cheatham, T. E., 3rd; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M., Jr.; Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J., The Amber biomolecular simulation programs. *Journal of Computational Chemistry* **2005,** 26, (16), 1668-88.

44. Walker, R. C.; Crowley, M. F.; Case, D. A., The implementation of a fast and accurate QM/MM potential method in Amber. *Journal of Computational Chemistry* **2008,** 29, (7), 1019-31.

45. Lindorff-Larsen, K.; Piana, S.; Palmo, K.; Maragakis, P.; Klepeis, J. L.; Dror, R. O.; Shaw, D. E., Improved side-chain torsion potentials for the Amber ff99SB protein force field. *Proteins* **2010,** 78, (8), 1950-8.

46. Thomas, A. S.; Mao, S.; Elcock, A. H., Flexibility of the bacterial chaperone trigger factor in microsecond-timescale molecular dynamics simulations. *Biophysical journal* **2013,** 105, (3), 732-44.

47. Wang, J.; Wang, W.; Kollman, P. A.; Case, D. A., Automatic atom type and bond type perception in molecular mechanical calculations. *Journal of molecular graphics & modelling* **2006,** 25, (2), 247-60.

48. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A., Development and testing of a general amber force field. *Journal of Computational Chemistry* **2004,** 25, (9), 1157-74.

49. Salomon-Ferrer, R.; Gotz, A. W.; Poole, D.; Le Grand, S.; Walker, R. C., Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. *J Chem Theory Comput* **2013,** 9, (9), 3878-88.

50. Treesuwan, W.; Hannongbua, S., Bridge water mediates nevirapine binding to wild type and Y181C HIV-1 reverse transcriptase--evidence from molecular dynamics simulations and MM-PBSA calculations. *Journal of molecular graphics & modelling* **2009,** 27, (8), 921-9.

51. Zhou, Z.; Madura, J. D., Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS. *Proteins* **2004,** 57, (3), 493-503.

52. Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E., 3rd, Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. *Accounts of chemical research* **2000,** 33, (12), 889-97.

53. Hou, T.; Wang, J.; Li, Y.; Wang, W., Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. *Journal of chemical information and modeling* **2011,** 51, (1), 69-82.